Trans women and transfeminine people taking HRT are far less likely to develop prostate cancer

Zinnia JonesConcerns over supposedly cancer-causing effects of cross-sex hormone therapy are an area in which public alarm has often pulled far ahead of the facts on transition and transgender health. For instance, in 2019, the Telegraph breathlessly reported that the “risk of breast cancer rises 46 times for trans women after hormone therapy”. What this framing omitted is that the study found trans women had a 70% lower likelihood of developing breast cancer compared to cis women, that the “absolute risk of breast cancer in transgender people remains low”, and that “following breast cancer screening guidelines for cisgender people seems sufficient for transgender people using hormone treatment” (de Blok et al., 2019).

Abigail Shrier, in her recent book Irreversible Damage: The Transgender Craze Seducing Our Teenage Daughters, referred to a “suspected risk” of uterine and endometrial cancer in trans men taking testosterone, then upgraded this suspicion to the overt claim that testosterone “can raise the risk of endometrial cancer significantly” in an interview at the Heritage Foundation’s Daily Signal; Jonathon Van Maren’s review of Shrier’s book makes the completely separate claim that puberty-blocking medications used for trans adolescents “create a higher risk of” cancer, an assertion that was not made by Shrier. Continue reading

Posted in Endocrinology, Media, Oncology, Transphobia and prejudice | Tagged , , , , | Leave a comment

Clascoterone, an upcoming topical antiandrogen for acne and hair loss treatment without systemic effects

Zinnia JonesFor trans men, transmasculine and nonbinary people who choose medical transition with testosterone, this treatment can sometimes lead to acne breakouts on the face or body. Testosterone has been found to causes increased skin production of sebum in trans men, which is a factor in the development of acne (Giltay & Gooren, 2000), and the Endocrine Society (Hembree et al., 2017) and the World Professional Association for Transgender Health (Coleman et al., 2012) have noted that acne can begin to develop as soon as one month after starting HRT.

Acne can represent a significant burden for trans people taking testosterone: Wierckx et al. (2014) reported that after 6 months of treatment, 82.4% of trans men developed facial acne and 88.2% experienced acne on their chest or back, and half of the participants in the study began using acne treatments such as topical benzoyl peroxide or oral antibiotics. Notably, Motosko et al. (2019) found that 52% of trans men on testosterone in their study sample experienced acne, compared to only 6.7% of cis men. Higher levels of testosterone also appear to be associated with a greater likelihood of developing acne (Park et al., 2019). Continue reading

Posted in Dermatology, Endocrinology, Transgender medicine | Tagged , , | Leave a comment

Don’t go bananas over spironolactone and potassium

Disclaimer: I am not a medical professional and this is not medical advice.

Zinnia JonesSpironolactone has recently been in the news due to apparently unfounded concerns that taking it could increase the chances of contracting pandemic coronavirus or suffering from more severe COVID-19, so this is a good time to examine one of the classic misconceptions about this medication: the potential risk of elevated levels of potassium.

While spironolactone is widely used as a part of transfeminine hormone therapy (particularly in areas such as the United States where the antiandrogen cyproterone acetate is not available) to inhibit the masculinizing action of testosterone in those who still have testes, this is not the purpose it was originally meant to serve. Instead, it’s one of a class of drugs known as potassium-sparing diuretics used to treat high blood pressure and congestive heart failure by promoting greater excretion of water through urination, reducing blood volume and therefore reducing blood pressure; in this role, its antiandrogenic action is a side effect. Continue reading

Posted in Endocrinology, Transgender medicine | Tagged , , , , , , | Leave a comment

June COVID-19 update: Reassuring data on spironolactone and ACE2 risks

Disclaimer: I am not a medical professional and this is not medical advice. Our understanding of the pandemic is evolving rapidly; this information may be superseded by later and more conclusive findings. This article was last updated on June 30, 2020.

Zinnia JonesAt the end of March, I addressed claims circulating in style and beauty publications about the medication spironolactone and its alleged connection to COVID-19 risk. Spironolactone works to block and suppress the action of testosterone and is sometimes prescribed for the hormonal treatment of acne in cis women, as well as being used to diminish the action of testosterone in trans women who still have testes. The concerns put forth by dermatologist Dr. Ellen Marmur and a handful of others posited that because spironolactone can increase the expression of the ACE2 receptor by cells of the human body, and the SARS-CoV-2 virus which causes COVID-19 must make use of this ACE2 receptor to enter and infect cells, taking spironolactone could therefore place one at greater risk of contracting COVID-19 or suffering a more severe course of the disease. For these reasons, Marmur had recommended to her patients that they discontinue spironolactone and use other medications for the treatment of acne. Continue reading

Posted in COVID-19, Endocrinology, Transgender medicine | Tagged , , | 2 Comments

We the Mudbloods: J. K. Rowling and the Trans-Exterminationists (Book 3)

Previously: J. K. Rowling and the Trans-Exterminationists, Book 2

Zinnia JonesRowling goes on to cite her own experience with domestic violence and sexual assault as representative of “huge numbers of women” who supposedly share her views:

I’ve been in the public eye now for over twenty years and have never talked publicly about being a domestic abuse and sexual assault survivor. . . . I’m mentioning these things now not in an attempt to garner sympathy, but out of solidarity with the huge numbers of women who have histories like mine, who’ve been slurred as bigots for having concerns around single-sex spaces.

This suggests that there is a natural progression from women experiencing abuse and assault at the hands of men, to these women opposing trans women’s access to single-sex spaces. It is unlikely that such a general effect exists. RAINN provides statistics showing that 1 in 6 American women have experienced rape or attempted rape during their lifetime, while 1 in 33 American men have experienced rape or attempted rape. More women than men are subjected to intimate partner violence as well. However, surveys consistently find that women are substantially more supportive of trans people and trans rights than men. Continue reading

Posted in Bathrooms and public accommodations, Personal, Politics and law, Replies, Sociological research, Trans youth, Transphobia and prejudice | Tagged , , , , | 4 Comments